
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The American Journal of Managed Care
over 23 years ago
Introductionover 23 years ago
Evaluating Health Plan Quality 3: Survey Measurement Propertiesover 23 years ago
What Do Physician Recommendations of Health Plans Mean?




